Anterior uveiti a a ide effect of topical brimonidine

PURPOE: To report anterior uveiti a a late ide-effect of topical brimonidine tartrate 0.2% (Alphagan; Allergan Inc., Irvine, California). METHOD: Four patient aged 79 to 91 (mean, 83) year, who developed acute anterior uveiti while uing topical brimonidine for chronic glaucoma, were clinically evaluated for caue of uveiti. When the inflammation had completely cleared, topical brimonidine wa recommenced in one eye only to determine cauality. REULT: All four patient developed acute granulomatou anterior uveiti, which reolved rapidly on topping brimonidine and receiving treatment with topical corticoteroid. The uveiti occurred 11 to 15 (mean, 13.8) month after commencement of brimonidine 0.2% twice daily. None of the patient had a previou hitory of uveiti, and no other identifiable caue of uveiti wa found. In all patient, on rechallenge with brimonidine intilled twice daily to one eye, uveiti recurred within 3 week in that eye only. CONCLUION: Thee finding ugget that brimonidine can caue anterior uveiti a a late ide effect. The inflammation ettle rapidly on topping the medication and on uing topical corticoteroid and recur on rechallenge with brimonidine.